IL2 and neoplasm: Despite only one study using metallic nanoparticles is under clinical trials (NCT03020017, Table 6), the potential of inorganic nanoparticles for tumor vaccination is supported by studies from the University of Minnesota (USA) that conducted phase II clinical trials using allogenic large multivalent immunogen (LMI) vaccines in silica particles combined with IL-2 for stage IV melanoma and breast cancer treatment (NCT00726739 and NCT00784524) [255].